12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Company News  |  Deals

Targacept, AstraZeneca deal

Targacept said AstraZeneca will advance AZD1446 into a Phase II trial as an adjunct treatment to donepezil in patients with mild to moderate Alzheimer's disease (AD). Targacept expects the trial...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >